SB-0110 / Sinopia Biosci - LARVOL DELTA

Sinopia Biosciences Publishes Preclinical Data in Science Translational Medicine Supporting SB-0110, a Novel PKA-II Modulator, for Parkinson’s Disease (The Manila Times) - "...anticipated first-in-human studies in 2027...In non-human primate (NHP) models of PD with established dyskinesia, SB-0107 and novel optimized derivatives, including SB-0110, significantly reduced dyskinesia severity while potentiating the antiparkinsonian benefits of levodopa; SB-0110 and SB-0107 demonstrated no meaningful activity across established Parkinson's drug targets, a large panel of GPCR targets, and an off-target safety-liability panel, supporting a differentiated mechanism with a favorable preclinical safety profile ahead of IND-enabling toxicology....The work further validates omics-guided discovery as an unbiased strategy for identifying differentiated therapeutic targets and drug candidates by capturing global cellular changes rather than focusing on preselected pathways or mechanisms."

First-in-human • New trial • Preclinical • Parkinson's Disease

A small molecule reduces both parkinsonism and l-dopa-induced dyskinesia in animal models of Parkinson's disease. (PubMed, Sci Transl Med) - "Deuterated analogs, including SB-0110, were developed that improved both pharmacokinetics and pharmacological effects. This dual effect, established safety profile of the parent compound, and improved properties of the deuterated analog support further development of this compound as an adjunct treatment to l-dopa therapy for PD."

Journal • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Sinopia Biosciences Selects Lead Clinical Candidate, Secures Funding to Advance into the Clinic for Parkinson’s Disease (Businesswire) - "Sinopia Biosciences, Inc...announced today that it has selected SB-0110 after extensive preclinical studies as its lead clinical candidate for Parkinson’s disease and levodopa-induced dyskinesia. By successfully meeting this milestone, Sinopia has triggered Phase II funding of its Fast Track Small Business Innovation Research (SBIR) grant for a cumulative funding of $3.3M awarded by the National Institute of Neurological Disorders and Stroke (NINDS), a part of the National Institutes of Health (NIH). Further, Sinopia has been selected to receive $2.0M in funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance SB-0110 into Phase 1 clinical trials."

Financing • CNS Disorders • Parkinson's Disease